Literature DB >> 21357295

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

P R S Lagacé-Wiens1, F Tailor, P Simner, M DeCorby, J A Karlowsky, A Walkty, D J Hoban, G G Zhanel.   

Abstract

The novel non-β-lactam β-lactamase inhibitor NXL104, in combination with cefepime, ceftazidime, ceftriaxone, amdinocillin, and meropenem, was tested against 190 extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, 94 AmpC-hyperproducing E. coli isolates, and 8 AmpC/ESBL-coexpressing E. coli isolates. NXL104 restored 100% susceptibility to the partner cephalosporins for all isolates tested. Amdinocillin and meropenem MICs were modestly improved (2 to 32 times lower) by NXL104. These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21357295      PMCID： PMC3088241          DOI： 10.1128/AAC.01722-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Authors:  Thérèse Stachyra; Marie-Claude Péchereau; Jean-Michel Bruneau; Monique Claudon; Jean-Marie Frère; Christine Miossec; Kenneth Coleman; Michael T Black
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Activity of mecillinam against ESBL producers in vitro.

Authors:  K Thomas; M J Weinbren; M Warner; N Woodford; D Livermore
Journal:  J Antimicrob Chemother       Date:  2005-12-14       Impact factor: 5.790

Review 3.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

4.  Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

Authors:  S Mushtaq; M Warner; G Williams; I Critchley; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-05-17       Impact factor: 5.790

5.  Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Jiancheng Zhang; Sunil Maharjan; Michel Doumith; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

6.  ampC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates.

Authors:  Dobryan M Tracz; David A Boyd; Romeo Hizon; Elizabeth Bryce; Allison McGeer; Marianna Ofner-Agostini; Andrew E Simor; Shirley Paton; Michael R Mulvey
Journal:  FEMS Microbiol Lett       Date:  2007-02-26       Impact factor: 2.742

Review 7.  Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.

Authors:  M Shahid; F Sobia; A Singh; A Malik; H M Khan; D Jonas; P M Hawkey
Journal:  Crit Rev Microbiol       Date:  2009       Impact factor: 7.624

8.  Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.

Authors:  Patricia J Baudry; Kim Nichol; Melanie DeCorby; Laura Mataseje; Michael R Mulvey; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

9.  A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.

Authors:  Ronen Ben-Ami; Jesús Rodríguez-Baño; Hande Arslan; Johann D D Pitout; Claudine Quentin; Esther S Calbo; Ozlem K Azap; Corinne Arpin; Alvaro Pascual; David M Livermore; Javier Garau; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

10.  NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Christine Miossec; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2008-08-09       Impact factor: 5.790
View more
  38 in total

1.  In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Authors:  Shawn Vasoo; Scott A Cunningham; Nicolynn C Cole; Peggy C Kohner; Sanjay R Menon; Kevin M Krause; Kelly A Harris; Partha P De; Tse Hsien Koh; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors:  Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 4.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.

Authors:  Premavathy Levasseur; Anne-Marie Girard; Christine Miossec; John Pace; Ken Coleman
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

7.  Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.

Authors:  Henri Merdjan; Manickam Rangaraju; Antoine Tarral
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

8.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

9.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 10.  The β-Lactams Strike Back: Ceftazidime-Avibactam.

Authors:  Evan J Zasowski; Jeffrey M Rybak; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2015-08       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.